Introduction

Cerebral creatine deficiency syndromes (CCDS) are a group of rare metabolic disorders first described in the 2000s.¹ CCDS results from genetic mutations that impair the synthesis and transport of a specific compound called creatine into the brain.^1,2 Creatine is an organic compound found in fish and red meat, and is necessary for recycling adenosine triphosphate (ATP), which is the energy currency of cells.^2,3

Specifically, in the brain, creatine plays a crucial role in helping neurons respond to sudden increases in brain activity, supporting synaptic signalling and providing a layer of protection to the neurons during high-stress situations. Due to its involvement in so many neural processes,  creatine is critical for brain development, as well as for new learning and memory formation.³

As such, a deficit in creatine means neurons cannot efficiently recycle ATP, which results in a chronic shortage of energy in the brain.² This shortage of energy has knock-on effects, creating lasting neuronal dysfunction and damage that leads to impaired neurodevelopment, abnormal neurotransmitter balance, oxidative stress, and mitochondrial dysfunction.⁴

There are three main subtypes of CCDS: GAMT deficiency, AGAT deficiency, and creatine transporter (SLC6A8) deficiency. Each of them affects the brain slightly differently, but ultimately leads to the same clinical manifestations.⁴

The individual subtypes are extremely rare, but their combined prevalence is likely higher than current estimates due to the overlap in root cause. Furthermore, due to overlapping symptoms and clinical manifestations, CCDS is usually misdiagnosed, as there are many other conditions that are also caused by dysfunction of these neural mechanisms.⁴ As a result, in many cases, CCDS may go undetected unless clinicians are already aware of the condition and specifically look for it using specialised imaging or biochemical screening tools.

Creatine synthesis and transport

To fully understand how CCDS occurs, we first need to dive into how the essential compound creatine, at the crux of this disorder, is formed and transported in the brain. 

Creatine is essential for energy metabolism in the brain and acts as a rapidly available energy buffer by helping cells regenerate ATP during periods of increased demand, such as during learning or motor activities.³ Creatine can also be synthesised through an enzymatic pathway. This enzymatic pathway is tightly regulated and consists of two steps:⁵

1. Creation of the GAA precursor molecule via the AGAT enzyme
2. The GAMT enzyme catalyses the GAA reaction to produce creatine

The first step to produce creatine is the biosynthesis of a molecule called guanidinoacetate (GAA), which is the precursor substance in the production of creatine.⁵ This process is carried out by an enzyme called AGAT, encoded by the GATM gene.⁶ AGAT is primarily active in the kidneys and pancreas and is responsible for a mechanism that combines parts of two amino acids, arginine with glycine, to form the GAA molecule.⁷ The synthesis of GAA via the AGAT enzyme is a crucial part of creatine synthesis, as without the GAA precursor molecule, creatine production will not take place.^5,6,7

The second step is catalysed by the GAMT enzyme that is encoded by the GAMT gene.⁵ This enzyme is primarily active in the liver. It is responsible for transferring a methyl group from a molecule called S-adenosylmethionine (SAM) to the GAA molecule, resulting in the production of creatine as a byproduct.^4,8 Therefore, GAMT is directly responsible for the biosynthesis of the creatine compound and thus plays a critical role in its production.⁸

Once synthesised, creatine enters the bloodstream and is distributed to various organs. However, the brain cannot synthesise enough creatine on its own and must get most of it from the blood. The SLC6A8 gene is essential for creatine import, as it encodes the creatine transporter (CRT), a specialised protein that transfers creatine from the bloodstream across the blood-brain barrier into brain tissue for neuronal use.^9,10,11

Thus, AGAT, GAMT and the CRT are three essential components of creatine synthesis and transport that are responsible for proper neuron function in the brain. The GATM, GAMT, and SLC6A8 genes, respectively, are the instructions that help carry out this process. Dysfunction at any of these levels will lead to a deficit, or even a complete absence of creatine in the brain, and will impair neural development and function.

Consequences of component deficiency

GAMT deficiency

GAMT enzyme deficiency means the enzyme is either dysfunctional or missing entirely; it occurs due to mutations in the GAMT gene, which is located on the short arm of chromosome 19; these errors lower the efficacy of the GAMT enzyme, resulting in the GAA to creatine conversion mechanism being blocked.^2,4,12 In a scenario where the enzyme is non-functional, very low amounts of creatine may still be produced, but in most cases, the conversion mechanism being blocked results in a complete halt in the synthesis of creatine.

This condition is autosomal recessive, meaning that both parents of the affected individual must have at least one faulty copy of the gene that was passed down to the individual.^5,12 Individuals with only one faulty copy of this gene do not display any symptoms and are considered carriers of CCDS.

This leads to: 

1. Reduced creatine levels in the brain 
2. GAA build up in the body and brain

Creatine is essential for brain cells to produce and recycle energy. Its deficiency means that the brain is not supplied with the necessary amount of energy, leading to widespread neurological dysfunction.⁵ Moreover, excess GAA is extremely toxic to the body, and high levels of GAA in the brain interfere with brain function and can cause irreversible damage to brain cells.⁸

GAMT deficiency is usually evident from early on, as most children with the condition show signs of neurological problems in infancy or early childhood.² The most common symptom of this condition is developmental delays. In less severe cases, the developmental delay can manifest as a speech impairment, but in most cases, the delay affects every aspect of infancy, including sitting, crawling, walking, and speaking.⁴ Many children with this genetic abnormality will also experience epileptic seizures, movement abnormalities, and display behaviours associated with hyperactivity or autism.^2,4,5

These symptoms largely manifest due to the brain’s inability to generate and use energy efficiently, as well as the toxic effects of high levels of GAA buildup.

AGAT deficiency

AGAT deficiency is the rarest form of CCDS, with only 25 cases reported in the medical literature worldwide.⁴ Similar to GAMT deficiency, it is also an autosomal recessive disorder that requires two faulty copies of the gene to be inherited; however, in this condition, the mutation occurs in the GATM gene on chromosome 19, responsible for coding the AGAT enzyme.

AGAT plays a crucial role in the biosynthesis of creatine as it initiates the very first step of creatine synthesis by combining arginine and glycine to form the precursor GAA compound.^5,6,7 In AGAT deficiency, this first step cannot occur, and therefore, GAA is not produced, which makes it impossible for creatine to be synthesised downstream.^6,7

The result is a pure creatine deficiency throughout the body, and in particular, the brain.⁷ Due to the essential role creatine plays in energy metabolism, its absence causes severe neurological and developmental problems.⁴ However, unlike GAMT deficiency, there is no build-up of toxic byproducts like GAA, because the precursor (GAA) is never formed in the first place.

AGAT deficiency shares many of the same symptoms as GAMT deficiency, such as developmental delays, seizures, and behavioural conditions (e.g., hyperactivity and autism).^2,4

However, despite the similar symptoms, it has a higher chance of being misdiagnosed as other developmental conditions due to its rarity. Furthermore, due to a lack of GAA toxicity as the precursor is never even formed, the symptoms are usually milder or more gradual in onset.

SlC6A8 mutations

The SLC6A8 gene is located on the X chromosome at Xq28; mutations here cause CRT  deficiency. Unlike GAMT and AGAT deficiencies, which follow autosomal recessive inheritance patterns, SLC6A8 mutations and CRT deficiency follow an X-linked inheritance pattern.¹¹

An X-linked inheritance pattern means that males, who have a single X chromosome, are 100% likely to have the condition and show symptoms if they inherited a faulty X chromosome.¹³ Females, on the otherhand, have two X chromosomes and therefore, both X chromosomes must be faulty for them to show symptoms. If only one of the X chromosomes carries the mutated gene, the other X chromosome can compensate for the mutation and lead to most individuals showing mild or no symptoms.¹³ As a result, most females with the mutation are likely to be asymptomatic carriers.

Because of its X-linked nature, CRT deficiency is the most common form of cerebral creatine deficiency syndrome.¹⁰

In individuals with SLC6A8 mutations, the CRT is either non-functional or less effective, resulting in unsuccessful importation of creatine across the blood-brain barrier.⁹ This results in severely reduced creatine levels in the brain, which leads to impaired energy metabolism in neurons.^9,10 As a result, brain cells are unable to maintain their energy supply during times of high activity, leading to neural dysfunction.

The common symptoms are developmental delays, epileptic seizures, and behavioural issues. ^4,11 Other symptoms include intellectual disabilities, executive function deficits, motor delays, and feeding difficulties.⁹ 

Summary

CCDS are rare neurometabolic disorders caused by genetic mutations that impair brain development and function due to insufficient creatine levels. Creatine is vital for maintaining energy balance in neurons, especially during periods of high demand, such as learning, movement, and neural signalling. Its deficiency causes widespread disruption in energy metabolism, contributing to developmental delays, seizures, cognitive impairment, and behavioural issues. There are three known forms of CCDS, each uniquely affects a different part of the creatine pathway:

• GAMT mutations block the conversion of GAA to creatine, resulting in creatine shortage and toxic GAA accumulation. It is autosomal recessive and typically presents early with severe neurological symptoms
• AGAT mutations are the rarest form of CCDS and disrupt the first step in creatine biosynthesis, preventing GAA formation. It also follows autosomal recessive inheritance. Symptoms may be milder but still include developmental delay and cognitive deficits
• SLC6A8 mutations are the most common form of CCDS, causing deficiency in the creatine transporter (CRT) gene on the X chromosome. This X-linked disorder prevents creatine from entering the brain and leads to similar clinical manifestations of CCDS

Although these disorders are rare individually, their combined prevalence is likely underestimated due to diagnostic overlap with conditions like autism, cerebral palsy, or epilepsy, making it a priority to find proper diagnostic tools to treat genetic defects associated with CCDS.